Thomas Valente, MD
Psychiatry · Leesburg, FLNPI 1467416511
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $796,101 of the $967,316 with a category attached, or 82.3%. 30 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 28.2% of the total. 2025 is the largest year on record at $270,227, 3.5 times the $77,603 reported in 2019. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,956 payments — averaging $494.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$273K
- Otsuka America Pharmaceutical, Inc.$215K
- Johnson & Johnson$109K
- Teva Pharmaceuticals USA, Inc.$103K
- E.r. Squibb & Sons, L.L.C.$78K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$52K
- plus $138K from 24 others
Across 17 payments — averaging $1714.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$17K
- Hoffmann-la Roche Limited$11K
- Boehringer Ingelheim$1K
What the payments were for
- Consulting fees$77,2418%
- Speaking & faculty fees$796,10182%
- Travel & lodging$51,8075%
- Food & beverage$41,9184%
- Education$2500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 405 | $272,648 |
| Otsuka America Pharmaceutical, Inc. | 331 | $214,733 |
| Johnson & Johnson | 220 | $108,523 |
| Teva Pharmaceuticals USA, Inc. | 236 | $103,091 |
| E.r. Squibb & Sons, L.L.C. | 111 | $78,458 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 124 | $52,149 |
| Alkermes, Inc. | 138 | $51,543 |
| AbbVie(2 entities) | 164 | $49,682 |
| Sunovion Pharmaceuticals Inc. | 54 | $13,189 |
| Boehringer Ingelheim | 14 | $8,594 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 17 | $6,695 |
| Luye Pharma (USA) Ltd. | 10 | $4,402 |
| Vanda Pharmaceuticals Inc. | 37 | $975 |
| Axsome Therapeutics, Inc. | 15 | $500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $423 |
| Lundbeck LLC | 18 | $305 |
| Indivior Inc. | 12 | $207 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Corium, LLC | 9 | $172 |
| H2-pharma, LLC | 1 | $150 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $150 |
| Genentech USA, Inc. | 1 | $127 |
| Supernus Pharmaceuticals, Inc. | 7 | $126 |
| Acadia Pharmaceuticals Inc | 2 | $67 |
| Ironshore Pharmaceuticals Inc. | 3 | $57 |
| Noven Therapeutics, LLC | 2 | $46 |
| Merck | 2 | $34 |
| Bausch Health US, LLC | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$264,612
- LYBALVI$171,209
- REXULTI$115,473
- ABILIFY MAINTENA$96,049
- INVEGA SUSTENNA$90,961
- INVEGA TRINZA$89,254
- COBENFY$55,439
- CAPLYTA$49,940
- VRAYLAR$46,971
- Austedo XR$43,390
- ABILIFY ASIMTUFII$32,317
- AUSTEDO$28,081
- UZEDY$27,797
- ARISTADA$23,880
- SPRAVATO$14,450
- LATUDA$12,199
- REJOYN$6,197
- ARISTADA INITIO$5,970
- ERZOFRI EXTENDED-RELEASE$4,250
- LUMRYZ$150
How this compares
$967,316 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 41 | $520,725 |
| Invega SustennaPaliperidone Palmitate | 117 | $365,784 |
| IngrezzaValbenazine Tosylate | 35 | $299,905 |
| RexultiBrexpiprazole | 125 | $217,068 |
| Invega TrinzaPaliperidone Palmitate | 19 | $206,790 |
| VraylarCariprazine Hcl | 90 | $144,427 |
| Abilify MaintenaAripiprazole | 46 | $134,930 |
| AustedoDeutetrabenazine | 14 | $107,545 |
| Abilify AsimtufiiAripiprazole | 16 | $97,580 |
| TrintellixVortioxetine Hydrobromide | 119 | $72,454 |
| CaplytaLumateperone Tosylate | 34 | $64,403 |
| NuplazidPimavanserin Tartrate | 13 | $64,036 |
| LybalviOlanzapine/Samidorphan Malate | 37 | $59,414 |
| AristadaAripiprazole Lauroxil | 18 | $59,406 |
| AplenzinBupropion Hbr | 13 | $51,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $103,091 | $628,27155 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $108,523 | $572,574136 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena, Abilify Asimtufii | $214,733 | $449,577187 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $272,648 | $299,90535 claims |
| AbbVieVraylar | $49,682 | $144,42790 claims |
| Alkermes, Inc.Lybalvi, Aristada | $51,543 | $118,82055 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $423 | $72,454119 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $52,149 | $64,40334 claims |
| Acadia Pharmaceuticals IncNuplazid | $67 | $64,03613 claims |
| Bausch Health US, LLCAplenzin | $32 | $51,14713 claims |
| MerckBelsomra | $34 | $17,69622 claims |
| Axsome Therapeutics, Inc.Auvelity | $500 | $13,52911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Leesburg
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
- Jose GamezHialeah$557K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.